ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

被引：5
|
作者：
Poei, Darin [1 ]
Ali, Sana [2 ]
Ye, Shirley [1 ]
Hsu, Robert [2 ,3 ]
机构：
[1] Univ Southern Calif, Dept Internal Med, Los Angeles, CA 90033 USA
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA 90033 USA
[3] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Med, Div Med Oncol, 1441 Eastlake Ave, Los Angeles, CA 90033 USA
来源：
CANCER DRUG RESISTANCE | 2024年 / 7卷
关键词：
NSCLC; ALK TKI; acquired resistance; alectinib; crizotinib; lorlatinib; ceritinib; brigatinib; CELL LUNG-CANCER; LYMPHOMA KINASE ALK; GENERATION SEQUENCING REVEALS; PREFERRED 1ST-LINE OPTION; FACTOR RECEPTOR EGFR; OPEN-LABEL; TYROSINE KINASE; PHASE-II; CRIZOTINIB RESISTANCE; ACQUIRED-RESISTANCE;
D O I：
10.20517/cdr.2024.25
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified as potent oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC). The discovery of ALK inhibition using a tyrosine kinase inhibitor (TKI) has dramatically improved the outcomes of patients with ALK-mutated NSCLC. However, the emergence of intrinsic and acquired resistance inevitably occurs with ALK TKI use. This review describes the molecular mechanisms of ALK TKI resistance and discusses management strategies to overcome therapeutic resistance.
引用
收藏
页数：22
相关论文
共 50 条
  • [41] Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies
    Hashemi, Mehrdad
    Zandieh, Mohammad Arad
    Talebi, Yasmin
    Rahmanian, Parham
    Shafiee, Sareh Sadat
    Nejad, Melina Maghsodlou
    Babaei, Roghayeh
    Sadi, Farzaneh Hasani
    Rajabi, Romina
    Abkenar, Zahra Oryan
    Rezaei, Shamin
    Ren, Jun
    Nabavi, Noushin
    Khorrami, Ramin
    Rashidi, Mohsen
    Hushmandi, Kiavash
    Entezari, Maliheh
    Taheriazam, Afshin
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 160
  • [42] Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
    Alexander, Peter B.
    Wang, Xiao-Fan
    FRONTIERS OF MEDICINE, 2015, 9 (02) : 134 - 138
  • [43] Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
    Brandon Bumbaca
    Wei Li
    Acta Pharmaceutica Sinica B, 2018, 8 (04) : 518 - 529
  • [44] Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
    Bumbaca, Brandon
    Lin, Wei
    ACTA PHARMACEUTICA SINICA B, 2018, 8 (04) : 518 - 529
  • [45] Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies
    Murphy, Conleth G.
    Dickler, Maura N.
    ENDOCRINE-RELATED CANCER, 2016, 23 (08) : R337 - R352
  • [46] Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
    Peter B. Alexander
    Xiao-Fan Wang
    Frontiers of Medicine, 2015, 9 : 134 - 138
  • [47] Facing inevitable PARPis resistance: Mechanisms and therapeutic strategies for breast cancer treatment
    Liu, Haixia
    Chen, Xiaohui
    Jia, Yimin
    Chen, Hengyi
    Wang, Xiaohui
    Liu, Guoxiang
    Luo, Yang
    INTERDISCIPLINARY MEDICINE, 2023, 1 (02):
  • [48] Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer
    Zeng, Yue
    Yu, Danlei
    Tian, Wentao
    Wu, Fang
    CURRENT OPINION IN ONCOLOGY, 2022, 34 (01) : 54 - 65
  • [49] MicroRNA-mediated autophagy and drug resistance in cancer: mechanisms and therapeutic strategies
    Wei, Jinxing
    Wang, Xianghui
    Yu, Duo
    Tu, Yanyang
    Yu, Yaoyu
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [50] The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
    Pan, Yue
    Deng, Chao
    Qiu, Zhenhua
    Cao, Chenghui
    Wu, Fang
    FRONTIERS IN ONCOLOGY, 2021, 11
12345